Memantina Pharmakern (Memantine Hydrochloride)

• Memantine Hydrochloride acts on the glutamatergic system and is used in the management of Alzheimer’s disease.
• Alzheimer’s disease (moderate to severe): improves cognition and daily functioning.
• Cognitive decline in Alzheimer’s: helps slow the rate of deterioration.
• Behavioral symptoms of Alzheimer’s: may reduce agitation and improve patient cooperation.

• Memantine Hydrochloride is a non‑competitive antagonist of the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel at a site distinct from the glutamate binding site, it reduces excessive calcium influx caused by prolonged glutamate activation, thereby decreasing excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Confusion: transient disorientation.
• Insomnia: difficulty initiating or maintaining sleep.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring medical attention.
• Cardiac arrhythmia: irregular heart rhythm.
• Severe skin rash: including Stevens‑Johnson syndrome.
• Hepatic injury: elevated liver enzymes or hepatitis.
• Suicidal thoughts: emergence of depressive ideation.
• Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction.

• Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential risks.
• Renal impairment: dose may need adjustment based on creatinine clearance.
• History of seizures: monitor closely for increased seizure activity.
• Cardiovascular disease: use with caution in patients with arrhythmias or hypertension.
• Concurrent NMDA antagonists: avoid combination to prevent additive neurotoxicity.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Memantine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Amantadine: increased risk of neurotoxicity.
• Ketamine: additive NMDA antagonism leading to excessive CNS depression.
• Other NMDA antagonists: heightened risk of adverse neurologic effects.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may diminish memantine’s cognitive benefits.
• Diuretics: can raise plasma concentrations of memantine.
• CNS depressants (e.g., benzodiazepines): may enhance dizziness and sedation.